After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been the ...
Mitchell Grant is a self-taught investor with over 5 years of experience as a financial trader. He is a financial content strategist and creative content editor. Khadija Khartit is a strategy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback